FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	OMB APPROVAL									
OMB Number: 3235-028										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol MEDICINOVA INC [MNOV]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
<u>IWAKI YUICHI</u>										-			X	Director			10% Ow	ner
(Last)	(F	irst)	(Middle)	3.	Date of Earliest Transaction (Month/Day/Year)						_	X	Officer (below)	give title		Other (s below)	pecify	
C/O MEDICINOVA, INC.				0:	01/27/2022							President and CEO						
4275 EXECUTIVE SQUARE, SUITE 300				L														
				— 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) LA JOLI	LA C	A	92037										X	Form fil	ed by One	Repoi	ting Person	
,												Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				Transaction ate Ionth/Day/	Execution Date,		Code (Instr.				4 and 5) Securitie Beneficia Owned F		s Formally (D) (ollowing (I) (I		Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	Amount (A) or (D)			Reported Transaction (Instr. 3 a	action(s)			Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, Trailing or Exercise (Month/Day/Year) if any		Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		s (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		kpiration ate	Title	Amou or Numb of Sha	er		(Instr. 4)			
Employee Stock Option (Right to Buy)	\$5.92	01/27/2022		A		302,500		01/27/2022	02	2/17/2031	Commor Stock	302,5	500	\$0	302,500	(1)	D	

Explanation of Responses:

1. On February 18, 2021, the reporting person was granted an option to purchase 550,000 shares of common stock. The option vests based on the satisfaction of certain performance criteria for the fiscal year ended December 31, 2021. Such performance criteria for 2021 were achieved at the 55% attainment level, resulting in vesting of the option as to 302,500 shares.

/s/ Yuichi Iwaki

01/31/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.